Table 2 Correlation between general clinical features and pre-NLR-PLR groups.

From: Combined pretreatment neutrophil-lymphocyte ratio and platelet-lymphocyte ratio predicts survival and prognosis in patients with non-metastatic nasopharyngeal carcinoma: a retrospective study

Characteristics

LRG (%) (n = 389)

MRG (%) (n = 152)

HRG (%) (n = 224)

p-Value

LRG vs. MRG

LRG vs. HRG

MRG vs. HRG

Gender

   

0.174

0.073

0.842

 Male

303 (77.9)

110 (72.4)

160 (71.4)

   

 Female

86 (22.1)

42 (27.6)

64 (28.6)

   

Age (years old)

   

0.712

0.463

0.357

 < 47

186 (47.8)

70 (46.1)

114 (50.9)

   

 ≥ 47

203 (52.2)

82 (53.9)

110 (49.1)

   

8th T stage

   

0.001*

 < 0.001*

0.504

 T1-T2

89 (22.9)

19 (12.5)

25 (11.2)

   

 T3

161 (41.4)

54 (35.5)

93 (41.5)

   

 T4

139 (35.7)

79 (52.0)

106 (47.3)

   

8th N stage

   

0.035*

0.585

0.132

 N0-N1

109 (28.0)

47 (30.9)

57 (25.4)

   

 N2

228 (58.6)

73 (48.0)

131 (58.5)

   

 N3

52 (13.4)

32 (21.1)

36 (16.1)

   

8th Clinical stage

   

 < 0.001*

0.002*

0.231

 I-II

26 (6.7)

6 (3.9)

5 (2.2)

   

 III

187 (48.1)

48 (31.6)

88 (39.3)

   

 IVa

176 (45.2)

98 (64.5)

131 (58.5)

   

ECOG

   

0.432

0.001*

0.065

 0

304 (78.1)

114 (75.0)

148 (66.1)

   

 1

85 (21.9)

38 (25.0)

76 (33.9)

   

Pathological type

   

1.000

0.001*

0.023*

 NKUC

384 (98.7)

150 (98.6)

209 (93.3)

   

 NKDC

2 (0.5)

1 (0.7)

11 (4.9)

   

 KSCC

3 (0.8)

1 (0.7)

4 (1.8)

   

Smoking

   

0.690

0.118

0.370

 No

254 (65.3)

102 (67.1)

160 (71.4)

   

 Yes

135 (34.7)

50 (32.9)

64 (28.6)

   

Drinking

   

0.357

0.638

0.651

 No

337 (86.6)

127 (83.6)

191 (85.3)

   

 Yes

52 (13.4)

25 (16.4)

33 (14.7)

   

Treatment

   

0.155

0.578

0.584

 IMRT

26 (6.7)

5 (3.3)

12 (5.4)

   

 CCRT

118 (30.3)

40 (26.3)

62 (27.7)

   

 CCRT+IC/AC

245 (63.0)

107 (70.4)

150 (66.9)

   

pre-HGB

   

 < 0.001*

 < 0.001*

 < 0.001*

 < 120 g/L

60 (15.4)

44 (28.9)

108 (48.2)

   

 ≥ 120 g/L

329 (84.6)

108 (71.1)

116 (51.8)

   

pre-ALB

   

0.042*

0.001*

0.444

 < 43 g/L

157 (40.4)

76 (50.0)

121 (54.0)

   

 ≥ 43 g/L

232 (59.6)

76 (50.0)

103 (46.0)

   

pre-LMR

   

 < 0.001*

 < 0.001*

 < 0.001*

 < 2.82

132 (33.9)

78 (51.3)

164 (73.2)

   

 ≥ 2.82

257 (66.1)

74 (48.7)

60 (26.8)

   

pre-CRP

   

0.234

 < 0.001*

0.001*

 < 10 mg/L

310 (79.7)

114 (75.0)

130 (58.0)

   

 ≥ 10 mg/L

79 (20.3)

38 (25.0)

94 (42.0)

   
  1. HRG high risk group, MRG medium risk group, LRG low risk group.
  2. *Indicates a significant difference among groups with p < 0.05.
Back to article page